Clik here to view.
Morinaga Milk’s Probiotic Bifidobacterium infantis M-63 Alleviates Mental...
TOKYO Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced new research showing that consumption of its proprietary probiotic Morinaga...
View ArticleClik here to view.
Bioventus在马来西亚上市DUROLANE®，并选中Athrotech作为独家经销伙伴
荷兰霍夫多普 — (美国商业资讯) — 骨愈合解决方案领域的全球领导者Bioventus正在马来西亚上市单次注射关节液骨关节炎(OA)治疗产品DUROLANE，并选中Athrotech作为面向马来西亚市场的独家经销伙伴。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20190130005291/zh-CN/...
View ArticleClik here to view.
森永乳业的益生菌婴儿双歧杆菌M-63可减轻洪灾受害者的精神压力
东京 (美国商业资讯) — 日本领先的乳制品公司森永乳业株式会社(Morinaga Milk Industry Co., Ltd., TOKYO:2264)今天宣布，与马来西亚理科大学(USM)合作的新研究显示，摄入该公司专利益生菌森永婴儿双歧杆菌M-63可改善马来西亚2014-2015年洪灾受害者的精神状态。...
View ArticleClik here to view.
Repare Therapeutics Announces a Strategic Partnership Agreement With ONO...
MONTREAL & CAMBRIDGE, Mass. Repare Therapeutics, Inc., a privately held precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific...
View ArticleClik here to view.
Takeda Scoops Prestigious Global Top Employers® Award for Second Year Running
OSAKA, Japan Takeda Pharmaceutical Company Limited [TOKYO: 4502 / NYSE: TAK], (“Takeda”) today announced it has become part of a select group of only 12 to receive global Top Employer® status for...
View ArticleClik here to view.
武田薬品: Global Top Employers® に2年連続で認定
大阪 （ビジネスワイヤ） – 当社は、このたび、「Global Top Employers® 2019」に認定されましたのでお知らせします。Global Top Employersは、毎年Top Employers Instituteが優れた人事制度を有する企業を認定するものであり、Global Top Employers®...
View ArticleClik here to view.
Clik here to view.
Prana Receives First Orphan Drug Designation from the FDA for the Treatment...
MELBOURNE, Australia & SAN FRANCISCO Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced the US Food and Drug Administration (FDA) has granted Orphan...
View ArticleClik here to view.
武田薬品：2018年度第3四半期（4-12月期）の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502)(NYSE:TAK)： 実質的な売上収益は＋4.8％、医療用医薬品の成長が牽引し、すべての地域で増収 実質ベースの売上収益の成長率は、タケダの成長ドライバー（消化器系疾患領域、オンコロジー、ニューロサイエンス、新興国事業）の＋10.5％の継続的な伸長により、対前年同期＋4.8％...
View ArticleClik here to view.
Takeda Reports Third Quarter FY2018 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue +4.8% year-to-date with growth of prescription drug portfolio in all regions Solid Underlying Revenue...
View ArticleClik here to view.
武田连续第二年荣膺享有盛誉的全球杰出雇主奖
日本大阪 (美国商业资讯)–武田药品工业株式会社[TOKYO: 4502 / NYSE: TAK]（“武田”）今天宣布其成为2019年荣膺全球杰出雇主(Top Employer®)奖项的十二家公司之一。此奖项认证成立于25年前，每年由杰出雇主调研机构(Top Employers...
View ArticleClik here to view.
With Completion of Neovia Acquisition, ADM Creates Premier Global Leader in...
CHICAGO Archer Daniels Midland Company (NYSE: ADM) announced today that it has successfully completed its €1.544 billion acquisition of Neovia, creating a global leader in value-added products and...
View ArticleClik here to view.
LEO Pharma Scientists Win Innovator of the Year 2019 Award from Innovation...
BALLERUP, Denmark LEO Pharma, a global leader in medical dermatology, today announced that two of the company’s scientists have been awarded Innovation Fund Denmark’s Innovator of the Year Award...
View ArticleClik here to view.
武田薬品のデング熱ワクチン候補がピボタル第3相有効性試験で主要評価項目を達成
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社[TSE:4502 / NYSE:TAK]（以下、武田薬品）は本日、当社デング熱ワクチン候補がピボタル第3相試験で主要有効性評価項目を達成したと発表しました。Tetravalent Immunization against Dengue Efficacy...
View ArticleClik here to view.
Agilent Announces Gas Chromatography Systems With Innovative Instrument...
SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A) today announced two new gas chromatography systems that incorporate innovative and intelligent ‘self-aware’ predictive technology, expanding...
View ArticleClik here to view.
BioventusがマレーシアでDUROLANE®を発売し、独占販売の提携企業にAthrotechを選定
蘭ホーフトドルプ （ビジネスワイヤ） — オーソバイオロジクス・ソリューションの世界的リーダー企業のBioventusは、変形性関節症治療用の関節内単回注射液DUROLANEをマレーシアで発売し、同市場での独占販売の提携企業にAthrotechを選定しました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：...
View ArticleClik here to view.
Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL –...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, has today announced results from its phase...
View ArticleClik here to view.
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from...
View ArticleClik here to view.
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the...
CAMBRIDGE, Mass. and OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS...
View ArticleClik here to view.
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase 3 ARCHES trial in men...
View Article